See more : JP 3E Holdings, Inc. (SPZI) Income Statement Analysis – Financial Results
Complete financial analysis of TMS Co., Ltd. (4891.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TMS Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Itafos Inc. (IFOS.V) Income Statement Analysis – Financial Results
- Michman Basad Ltd (MCMN.TA) Income Statement Analysis – Financial Results
- VSee Lab, Inc./iDoc Virtual Telehealth Solutions, Inc. (VSEEW) Income Statement Analysis – Financial Results
- EverArc Holdings Limited (EVRA.L) Income Statement Analysis – Financial Results
- Jaipan Industries Limited (JAIPAN.BO) Income Statement Analysis – Financial Results
TMS Co., Ltd. (4891.T)
About TMS Co., Ltd.
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.95B | 0.00 |
| Cost of Revenue | 6.95M | 6.60M | 201.66M | 4.09M |
| Gross Profit | -6.95M | -6.60M | 1.74B | -4.09M |
| Gross Profit Ratio | 0.00% | 0.00% | 89.64% | 0.00% |
| Research & Development | 607.73M | 297.90M | 304.28M | 603.24M |
| General & Administrative | 335.53M | 222.25M | 506.61M | 117.92M |
| Selling & Marketing | -22.53M | 0.00 | 0.00 | 0.00 |
| SG&A | 313.00M | 222.25M | 506.61M | 117.92M |
| Other Expenses | 23.00M | -627.00K | 155.00K | 605.00K |
| Operating Expenses | 943.25M | 520.15M | 810.88M | 721.16M |
| Cost & Expenses | 943.25M | 520.15M | 810.88M | 721.16M |
| Interest Income | 42.00K | 89.00K | 77.00K | 102.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.95M | 6.60M | 737.00K | 4.09M |
| EBITDA | -937.00M | -854.88M | 1.08B | -717.89M |
| EBITDA Ratio | 0.00% | 0.00% | 63.27% | 0.00% |
| Operating Income | -943.25M | -520.15M | 1.14B | -721.16M |
| Operating Income Ratio | 0.00% | 0.00% | 58.34% | 0.00% |
| Total Other Income/Expenses | -15.84M | -341.32M | -56.33M | -826.00K |
| Income Before Tax | -959.09M | -861.47M | 1.08B | -721.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | 55.45% | 0.00% |
| Income Tax Expense | 950.00K | -545.00K | 2.45M | 950.00K |
| Net Income | -960.04M | -860.93M | 1.08B | -722.93M |
| Net Income Ratio | 0.00% | 0.00% | 55.32% | 0.00% |
| EPS | -26.02 | -25.28 | 53.36 | -20.89 |
| EPS Diluted | -26.02 | -25.28 | 53.36 | -20.89 |
| Weighted Avg Shares Out | 36.90M | 34.05M | 20.18M | 34.60M |
| Weighted Avg Shares Out (Dil) | 36.90M | 34.05M | 20.18M | 34.60M |
Source: https://incomestatements.info
Category: Stock Reports